三种样本直答平台检测SARS-CoV-2的临床评估
研究评估了Cepheid Xpert Xpress、Abbott ID NOW和GenMark ePlex三种样本直答分子诊断平台对108例有症状患者鼻咽拭子的分析灵敏度、临床性能和工作流程。Xpert Xpress检测下限最低(100 copies/ml 100%检出)且阳性符合率最高(98.3%),ID NOW出结果最快(约17分钟)但灵敏度和阳性符合率最低(87.7%),ePlex居中。三种方法阴性符合率均为100%。
要点
- Xpert Xpress分析灵敏度最高(100 copies/ml 100%检出),阳性符合率98.3%。
- ID NOW出结果最快(约17分钟),但检测下限20,000 copies/ml,阳性符合率87.7%。
- 三种平台阴性符合率均为100%,临床选择需权衡速度与灵敏度。
核心结论
- Xpert Xpress在三种平台中分析灵敏度和阳性符合率最高,ID NOW速度最快但性能最低。
研究设计与样本
- 研究纳入108例有症状患者的鼻咽拭子,评估三种样本直答分子诊断平台的分析灵敏度、临床性能和工作流程。
主要发现
- Xpert Xpress检测下限为100 copies/ml(100%检出),ePlex为1,000 copies/ml(100%检出),ID NOW为20,000 copies/ml。
- Xpert Xpress阳性符合率为98.3%,ePlex为91.4%,ID NOW为87.7%。
- 三种方法阴性符合率均为100%。
- ID NOW每标本出结果时间约17分钟,Xpert Xpress约46分钟,ePlex约1.5小时。
关键数值与推荐
- Xpert Xpress:检测下限100 copies/ml,阳性符合率98.3%,阴性符合率100%,出结果时间约46分钟。
- ePlex:检测下限1,000 copies/ml,阳性符合率91.4%,阴性符合率100%,出结果时间约1.5小时。
- ID NOW:检测下限20,000 copies/ml,阳性符合率87.7%,阴性符合率100%,出结果时间约17分钟。
临床怎么用
- 需高灵敏度检测时优先选择Xpert Xpress,需快速出结果时可考虑ID NOW但需知晓其较低的分析灵敏度和阳性符合率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread across the globe. As part of the worldwide response, many molecular diagnostic platforms have been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA) to identify SARS-CoV-2 positive patients. Our objective was to evaluate three sample-to-answer molecular diagnostic platforms (Cepheid Xpert Xpress SARS-CoV-2 [Xpert Xpress], Abbott ID NOW COVID-19 [ID NOW], and GenMark ePlex SARS-CoV-2 Test [ePlex]) to determine analytical sensitivity, clinical performance, and workflow for the detection of SARS-CoV-2 in nasopharyngeal swabs from 108 symptomatic patients. We found that Xpert Xpress had the lowest limit of detection (100% detection at 100 copies/ml), followed by ePlex (100% detection at 1,000 copies/ml), and ID NOW (20,000 copies/ml). Xpert Xpress also had highest positive percent agreement (PPA) compared to our reference standard (98.3%) followed by ePlex (91.4%) and ID NOW (87.7%). All three assays showed 100% negative percent agreement (NPA). In the workflow analysis, ID NOW produced the lowest time to result per specimen (∼17 min) compared to Xpert Xpress (∼46 min) and ePlex (∼1.5 h), but what ID NOW gained in rapid results, it lost in analytical and clinical performance. ePlex had the longest time to results and showed a slight improvement in PPA over ID NOW. Information about the clinical and analytical performance of these assays, as well as workflow, will be critical in making informed and timely decisions on testing platforms.
引用
- Zhen W, Smith E, Manji R, et al. Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2. J Clin Microbiol. 2020. PMID: 32332061. doi:10.1128/JCM.00783-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。